Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RAPT 
RAPT Therapeutics Inc (RAPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: RAPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $65
1 Year Target Price $65
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.16% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 864.58M USD | Price to earnings Ratio - | 1Y Target Price 65 |
Price to earnings Ratio - | 1Y Target Price 65 | ||
Volume (30-day avg) 7 | Beta 0.46 | 52 Weeks Range 5.66 - 42.39 | Updated Date 01/9/2026 |
52 Weeks Range 5.66 - 42.39 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.66 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.35% | Return on Equity (TTM) -85.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 709831175 | Price to Sales(TTM) 411.22 |
Enterprise Value 709831175 | Price to Sales(TTM) 411.22 | ||
Enterprise Value to Revenue 677.37 | Enterprise Value to EBITDA -10.73 | Shares Outstanding 27710871 | Shares Floating 18344319 |
Shares Outstanding 27710871 | Shares Floating 18344319 | ||
Percent Insiders 0.25 | Percent Institutions 65.59 |
Upturn AI SWOT
RAPT Therapeutics Inc
Company Overview
History and Background
RAPT Therapeutics Inc. was founded in 2019 through the merger of Bionic Sight and Bionic Cancer, and later rebranded to RAPT Therapeutics. The company is focused on developing novel small molecule therapeutics for cancer and inflammatory diseases. It has advanced its lead programs into clinical trials.
Core Business Areas
- Oncology: Developing targeted therapies for cancer, aiming to address resistance mechanisms and unmet needs.
- Inflammatory Diseases: Investigating small molecule inhibitors for inflammatory conditions, targeting key pathways involved in disease progression.
Leadership and Structure
RAPT Therapeutics is led by a management team with experience in drug development and the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biotechnology company, with departments focused on R&D, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- RARE-303: A novel oral small molecule antagonist of the aryl hydrocarbon receptor (AhR), being developed for the treatment of cancer and inflammatory diseases. Competitors include other companies developing AhR modulators or targeting similar pathways in oncology and immunology.
- RAVT-101: A novel oral small molecule antagonist of the FLT3 pathway, intended for the treatment of certain types of cancer. Competitors include other FLT3 inhibitors and companies developing targeted therapies for hematological malignancies.
Market Dynamics
Industry Overview
The oncology and immunology markets are characterized by rapid innovation, significant unmet medical needs, and intense competition. Biotechnology companies are focused on developing targeted therapies and immunotherapies with improved efficacy and safety profiles. Regulatory hurdles and lengthy development timelines are inherent to the industry.
Positioning
RAPT Therapeutics is positioned as a clinical-stage biotechnology company focused on developing targeted small molecule therapies for challenging diseases. Its competitive advantage lies in its novel drug candidates targeting specific pathways with potential for both oncology and inflammatory indications.
Total Addressable Market (TAM)
The TAM for oncology and inflammatory diseases is substantial, measured in hundreds of billions of dollars globally. RAPT Therapeutics aims to capture a segment of this market with its differentiated therapeutic candidates, but its current market penetration is negligible as it is still in clinical development.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potentially differentiated mechanisms of action.
- Experienced management team with a track record in drug development.
- Focus on addressing significant unmet needs in oncology and inflammatory diseases.
- Strong scientific foundation and pipeline.
Weaknesses
- Clinical-stage company with no approved products, leading to high R&D costs and no revenue generation.
- Reliance on clinical trial success for future revenue.
- Limited financial resources compared to larger pharmaceutical companies.
- Execution risk in clinical development and regulatory approval.
Opportunities
- Advancement of lead drug candidates through clinical trials and potential regulatory approval.
- Expansion into new indications or patient populations.
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
- Growing market demand for innovative cancer and inflammatory disease treatments.
Threats
- Failure of drug candidates in clinical trials.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory challenges and delays in approval processes.
- Changes in healthcare policy and reimbursement landscapes.
- Financing risks and the need for ongoing capital raises.
Competitors and Market Share
Key Competitors
- Amgen Inc. (AMGN)
- Bristol Myers Squibb Company (BMY)
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
- Eli Lilly and Company (LLY)
Competitive Landscape
RAPT Therapeutics faces competition from large, established pharmaceutical companies with significant resources and existing portfolios in oncology and immunology. Its advantages lie in its targeted approach and potentially novel mechanisms, but it faces disadvantages in terms of scale, financial capacity, and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for RAPT Therapeutics is characterized by pipeline advancement and expansion of its R&D activities, rather than revenue growth. The company has been growing its operational scale and clinical program scope.
Future Projections: Future growth projections are heavily contingent on the successful clinical development and regulatory approval of its lead drug candidates, RARE-303 and RAVT-101. Analyst estimates are typically focused on potential peak sales if products are approved.
Recent Initiatives: Recent initiatives include the advancement of its lead candidates into clinical trials, the initiation of new clinical studies, and ongoing efforts to secure financing for its development programs.
Summary
RAPT Therapeutics is a clinical-stage biopharmaceutical company with promising drug candidates in oncology and inflammatory diseases. Its strengths lie in its innovative pipeline and experienced team, but it faces significant challenges due to its lack of approved products, high R&D costs, and intense industry competition. Success hinges on positive clinical trial outcomes and effective fundraising to navigate the long development path.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial Data Aggregators (e.g., Yahoo Finance, Google Finance)
- Industry Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Financial data and market share figures are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RAPT Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-10-31 | CEO, President & Director Dr. Brian Russell Wong M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.rapt.com |
Full time employees 60 | Website https://www.rapt.com | ||
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.